Chiesi latest to spend big in rare diseases with Amryt buy

Anglo-Irish company Amryt Pharma (LSE: AMYT) has long held ambitions of following in the footsteps of Shire, the rare diseases company that was acquired by Takeda (TYO: 4502) four years ago.

Amryt may not have quite grown to Shire’s size, but its acquisition by privately-held Italian drugmaker Chiesi has vindicated the ambitious approach of its leadership team in turning it into one of the most exciting emerging companies in the rare diseases space.

"We are further expanding our commitment to people living with rare diseases, the majority of which still have no cure or approved treatment"